National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-CD200 monoclonal antibody ALXN6000
A humanized monoclonal antibody directed against the human immunosuppressive molecule CD200 (OX-2) with potential immunomodulating and antineoplastic activities. Anti-CD200 monoclonal antibody ALXN6000 binds to CD200, blocking the binding of CD200 to its receptor, CD200R, present on cells of the macrophage lineage; inhibition of CD200 may augment the cytotoxic T-lymphocyte (CTL) mediated immune response against CD200-expressing tumor cells. CD200 is a type 1a transmembrane protein, related to the B7 family of co-stimulatory receptors, and is upregulated on the surface of multiple hematologic malignant cells; this transmembrane protein appears to be involved in the downregulation of a Th1 (helper T cell) immune response. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:ALXN6000



Previous:anti-CD137 monoclonal antibody, anti-CD19 fully human monoclonal antibody MDX-1342, anti-CD19-DM4 immunoconjugate SAR3419, anti-CD20 monoclonal antibody AME-133v, anti-CD20 monoclonal antibody R7159
Next:anti-CD22 immunotoxin CAT-8015, anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1), anti-CD30 monoclonal antibody MDX-1401, anti-CD30 monoclonal antibody XmAb2513, anti-CD33 monoclonal antibody-DM4 conjugate AVE9633

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov